ReMuS in America - poster at the prestigious American Academy of Neurology Congress
ReMuS in America - a poster at the prestigious American Academy of Neurology Congress In April 2025, the AAN Congress took place, where Dr. Dominika Št'astná presented the results of the [...]
Get to know the ReMuS registry
Get to know the ReMuS Registry For the presentation of the ReMuS Registry at the ECTRIMS International Congress on Neuroimmunological Diseases, we have prepared a short presentation that will reveal what is hidden under the hood of this [...]
Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry
A new study published in the Journal of Central Nervous System Disease provides insights into the efficacy of cladribine in the treatment of multiple sclerosis (MS) in real-world clinical practice. The paper uses data from the Czech nationwide ReMuS registry and...
Neurologists: all patients must receive high quality care | 2024 ReMuS Registry Press Conference
If a person becomes ill with multiple sclerosis (MS), it should not matter whether they live in Cheb, Kolín or Frýdek Místek. The same care should be provided in all centres throughout the Czech Republic. Thanks to the Patient Register...
Big Multiple Sclerosis Data network: an international registry research network
Article doc. Anna Glaser from Karolinska Institutet, Sweden, focuses on the importance and contribution of European multiple sclerosis registries, specifically the Big Multiple Sclerosis Data Network (BMSD) project, in which ReMuS is actively involved...
The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe
In their new study, a team led by Richard Nicholas looked at how health systems in different countries influence clinical diagnosis and access to treatment for multiple sclerosis...
Is breastfeeding in MS harmful or not? An answer from real-world Czech data
The original article by Pavel Hradílek, M.D., Ph.D. from the University Hospital Ostrava based on the ReMuS registry data was published in the journal Multiple Sclerosis and Related Disorders. Because the influence of breastfeeding and its duration on the course of multiple sclerosis is unclear, the authors analyzed real data on breastfeeding women with MS and the course of their disease...
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Expert article by Ing. Tereza Hrnčiarová, Ph.D. from the 1st Medical Faculty of Charles University deals with the issue of treatment strategies in relapsing-remitting multiple sclerosis. Her work is based on data from the Czech ReMuS registry and the Swedish SMSR (Swedish MS Registry). It builds on the...
Treatment of Multiple Sclerosis is Experiencing a Revolution | ReMuS Registry Press Conference 2023
To mark the approaching World Multiple Sclerosis (MS) Day, the ReMuS Patient Registry held its traditional press conference on 25 May 2023. The conference presented the most up-to-date data on MS and the practical achievements that the ReMuS Registry has been able to implement during its 10 years of existence...
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021
Multiple sclerosis is a serious neuroimmunological disease and data on its incidence and treatment are systematically and longitudinally evaluated by the national ReMuS registry. Trends in the treatment of patients in the Czech Republic were discussed by Dominika Št'astná, M.D., Ph.D. from the General University Hospital in Prague in her...